Literature DB >> 25767261

Novel insights into the function and dynamics of extracellular matrix in liver fibrosis.

Morten A Karsdal1, Tina Manon-Jensen2, Federica Genovese2, Jacob H Kristensen2, Mette J Nielsen2, Jannie Marie B Sand2, Niels-Ulrik B Hansen2, Anne-Christine Bay-Jensen2, Cecilie L Bager2, Aleksander Krag3, Andy Blanchard4, Henrik Krarup5, Diana J Leeming2, Detlef Schuppan6.   

Abstract

Emerging evidence suggests that altered components and posttranslational modifications of proteins in the extracellular matrix (ECM) may both initiate and drive disease progression. The ECM is a complex grid consisting of multiple proteins, most of which play a vital role in containing the essential information needed for maintenance of a sophisticated structure anchoring the cells and sustaining normal function of tissues. Therefore, the matrix itself may be considered as a paracrine/endocrine entity, with more complex functions than previously appreciated. The aims of this review are to 1) explore key structural and functional components of the ECM as exemplified by monogenetic disorders leading to severe pathologies, 2) discuss selected pathological posttranslational modifications of ECM proteins resulting in altered functional (signaling) properties from the original structural proteins, and 3) discuss how these findings support the novel concept that an increasing number of components of the ECM harbor signaling functions that can modulate fibrotic liver disease. The ECM entails functions in addition to anchoring cells and modulating their migratory behavior. Key ECM components and their posttranslational modifications often harbor multiple domains with different signaling potential, in particular when modified during inflammation or wound healing. This signaling by the ECM should be considered a paracrine/endocrine function, as it affects cell phenotype, function, fate, and finally tissue homeostasis. These properties should be exploited to establish novel biochemical markers and antifibrotic treatment strategies for liver fibrosis as well as other fibrotic diseases.
Copyright © 2015 the American Physiological Society.

Entities:  

Keywords:  collagen; cytokine; endocrine; extracellular fibrogenesis; integrin; laminin; matrix metalloproteinase; posttranslational modification; proteoglycan

Mesh:

Substances:

Year:  2015        PMID: 25767261      PMCID: PMC4437019          DOI: 10.1152/ajpgi.00447.2014

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  389 in total

1.  Appearance of denuded hepatic stellate cells and their subsequent myofibroblast-like transformation during the early stage of biliary fibrosis in the rat.

Authors:  L H Tao; H Enzan; Y Hayashi; E Miyazaki; T Saibara; M Hiroi; M Toi; N Kuroda; K Naruse; Y L Jin; L M Guo
Journal:  Med Electron Microsc       Date:  2000

Review 2.  Portal tract fibrogenesis in the liver.

Authors:  Giuliano Ramadori; Bernhard Saile
Journal:  Lab Invest       Date:  2004-02       Impact factor: 5.662

3.  Transforming growth factor-beta1 stimulates the synthesis of basement membrane proteins laminin, collagen type IV and entactin in rat liver sinusoidal endothelial cells.

Authors:  K Neubauer; M Krüger; F Quondamatteo; T Knittel; B Saile; G Ramadori
Journal:  J Hepatol       Date:  1999-10       Impact factor: 25.083

4.  Collagens in the liver extracellular matrix bind hepatocyte growth factor.

Authors:  D Schuppan; M Schmid; R Somasundaram; R Ackermann; M Ruehl; T Nakamura; E O Riecken
Journal:  Gastroenterology       Date:  1998-01       Impact factor: 22.682

Review 5.  Liver fibrosis: from the bench to clinical targets.

Authors:  M Pinzani; K Rombouts
Journal:  Dig Liver Dis       Date:  2004-04       Impact factor: 4.088

6.  Linking hematopoiesis to endochondral skeletogenesis through analysis of mice transgenic for collagen X.

Authors:  Olena Jacenko; Douglas W Roberts; Michelle R Campbell; Patricia M McManus; Catherine J Gress; Zhuliang Tao
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

Review 7.  Therapy for fibrotic diseases: nearing the starting line.

Authors:  Scott L Friedman; Dean Sheppard; Jeremy S Duffield; Shelia Violette
Journal:  Sci Transl Med       Date:  2013-01-09       Impact factor: 17.956

8.  Collagen binding specificity of the discoidin domain receptors: binding sites on collagens II and III and molecular determinants for collagen IV recognition by DDR1.

Authors:  Huifang Xu; Nicolas Raynal; Stavros Stathopoulos; Johanna Myllyharju; Richard W Farndale; Birgit Leitinger
Journal:  Matrix Biol       Date:  2010-10-28       Impact factor: 11.583

Review 9.  Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets.

Authors:  A M Gressner; R Weiskirchen
Journal:  J Cell Mol Med       Date:  2006 Jan-Mar       Impact factor: 5.310

10.  Macrophage activation in acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Jonas Christian Schupp; Harald Binder; Benedikt Jäger; Giuseppe Cillis; Gernot Zissel; Joachim Müller-Quernheim; Antje Prasse
Journal:  PLoS One       Date:  2015-01-15       Impact factor: 3.240

View more
  78 in total

1.  Endoplasmic reticulum oxidase 1α is critical for collagen secretion from and membrane type 1-matrix metalloproteinase levels in hepatic stellate cells.

Authors:  Mizuki Fujii; Akihiro Yoneda; Norio Takei; Kaori Sakai-Sawada; Marina Kosaka; Kenjiro Minomi; Atsuro Yokoyama; Yasuaki Tamura
Journal:  J Biol Chem       Date:  2017-08-03       Impact factor: 5.157

2.  Inhibition of mast cell-secreted histamine decreases biliary proliferation and fibrosis in primary sclerosing cholangitis Mdr2(-/-) mice.

Authors:  Hannah Jones; Laura Hargrove; Lindsey Kennedy; Fanyin Meng; Allyson Graf-Eaton; Jennifer Owens; Gianfranco Alpini; Christopher Johnson; Francesca Bernuzzi; Jennifer Demieville; Sharon DeMorrow; Pietro Invernizzi; Heather Francis
Journal:  Hepatology       Date:  2016-07-30       Impact factor: 17.425

3.  Serum endotrophin identifies optimal responders to PPARγ agonists in type 2 diabetes.

Authors:  Morten A Karsdal; Kim Henriksen; Federica Genovese; Diana J Leeming; Mette J Nielsen; Bente J Riis; Claus Christiansen; Inger Byrjalsen; Detlef Schuppan
Journal:  Diabetologia       Date:  2016-09-08       Impact factor: 10.122

4.  Strategies Targeting the Innate Immune Response for the Treatment of Hepatitis C Virus-Associated Liver Fibrosis.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

5.  Growing a whole porcine liver organ ex situ for six hours without red blood cells or hemoglobin.

Authors:  Jing Dong; Lingling Xia; Hefang Shen; Congwen Bian; Sujin Bao; Min Zhang; Yiqi Du; Yan Dai; Lijuan Zhao; Yuanhong Xu; Qiru Xiong; Jianjian Xu; Lili Xu
Journal:  Am J Transl Res       Date:  2016-06-15       Impact factor: 4.060

Review 6.  The liver fibrosis niche: Novel insights into the interplay between fibrosis-composing mesenchymal cells, immune cells, endothelial cells, and extracellular matrix.

Authors:  Michitaka Matsuda; Ekihiro Seki
Journal:  Food Chem Toxicol       Date:  2020-07-05       Impact factor: 6.023

Review 7.  Extracellular matrix as a driver of progressive fibrosis.

Authors:  Jeremy Herrera; Craig A Henke; Peter B Bitterman
Journal:  J Clin Invest       Date:  2018-01-02       Impact factor: 14.808

Review 8.  Resolution of organ fibrosis.

Authors:  Joon-Il Jun; Lester F Lau
Journal:  J Clin Invest       Date:  2018-01-02       Impact factor: 14.808

9.  Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis.

Authors:  Michitaka Matsuda; Ekihiro Seki
Journal:  Semin Liver Dis       Date:  2020-04-02       Impact factor: 6.115

10.  Inhibition of IRF3 expression reduces TGF-β1-induced proliferation of hepatic stellate cells.

Authors:  Ming-ming Ni; Tao Xu; Ya-rui Wang; Ying-hua He; Qun Zhou; Cheng Huang; Xiao-ming Meng; Jun Li
Journal:  J Physiol Biochem       Date:  2015-11-26       Impact factor: 4.158

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.